United States: CMS Proposes Major Changes To Medicare Clinical Lab Test Payment Policy

Last Updated: October 5 2015
Article by Debra A. McCurdy

On October 1, 2015, the Centers for Medicare & Medicaid Services (CMS) published its long-awaited proposed rule to base Medicare clinical laboratory fee schedule (CLFS) reimbursement on private insurance payment amounts beginning January 1, 2017. CMS estimates that the new policy, which was mandated by the Protecting Access to Medicare Act of 2014 (PAMA), will reduce Medicare CLFS payments by $360 million in FY 2017 and by $5.14 billion over 10 years. CMS will accept comments on the proposed rule until November 24, 2015.

The proposed rule would establish both reporting and payment provisions for clinical diagnostic laboratory tests (CDLTs). Note that CMS proposes different requirements for a subset of CDLTs that CMS determines to be "advanced diagnostic laboratory tests" (ADLTs). As defined by PAMA, an ADLT is a CDLT that is offered and furnished only by a single laboratory and not sold for use by a laboratory other than the original developing laboratory (or a successor owner) and that meets one of the following criteria: (1) the test is an analysis of multiple biomarkers of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or proteins combined with a unique algorithm to yield a single patient-specific result (CMS proposes more specific standards to meet this criterion); (2) the test is cleared or approved by the Food and Drug Administration; or (3) the test meets other similar criteria established by the Secretary (CMS is not proposing additional criteria at this time). CMS proposes to require laboratories to submit evidence to support their application for ADLT status.

Reporting Requirements

With regard to reporting, the proposed rule would require "applicable laboratories" to report to CMS specified "applicable information" about payment rates paid by private payors for each CDLT and the volumes of tests furnished during a specified period. CMS proposes to define an ''applicable laboratory'' as one that receives (1) $50,000 or more in Medicare revenues from laboratory services in a data collection period, and (2) more than 50% of its Medicare revenues for the entire organization from services paid by under the CLFS and the Medicare Physician Fee Schedule. The applicable laboratory will be the Taxpayer Identification Number (TIN) level entity, which will report for all of its National Provider Identifier (NPI) level components. CMS does not expect hospital laboratories to be considered applicable laboratories, and the agency estimates that more than 50% of independent laboratories and more than 90% of physician offices will be exempt from reporting private payor data under the low expenditure criterion.

CMS proposes that applicable information to be reported would include: (1) the payment rate paid by each private payor for each CLFS test (by HCPCS code) during the data collection period; and (2) the volume of such tests for each such payor. As mandated by the statute, CMS proposes to define "private payor'' as a health insurance issuer or a group health plan, a Medicare Advantage plan under Medicare Part C, or a Medicaid managed care organization. The payment rate reported by a laboratory must reflect all discounts, rebates, coupons, and other price concessions, and it would be inclusive of all patient cost sharing amounts. CMS proposes not to include information about tests for which payment is made on a capitated basis. The proposed rule includes detailed discussion of the concepts and terms embedded in its definition of the payment rate.

Payment Provisions

With regard to payment, subject to certain exceptions, the payment amount for a CDLT furnished on or after January 1, 2017 (other than new tests) would equal the weighted median of private payor rates determined for the test, based on the data reported by laboratories during the data collection period. CMS proposes its methodology for implementing a PAMA provision providing that the payment amount for a test cannot be reduced by more than 10% compared to the previous year's payment for the first three years of the policy (2017-2019) and not by more than 15% for the subsequent three years (2020-2022). For new and existing tests (other than new ADLTs) for which CMS receives no applicable information to calculate a weighted median, CMS proposes that payment rates would be determined by using crosswalking or gapfilling methods.

New ADLTs would be paid at actual list charge for a minimum of three quarters. CMS proposes to define actual list charge as the publicly-available rate on the first day the new ADLT is obtainable by a patient who is covered by private insurance, or marketed to the public as a test a patient can receive, even if the test has not yet been performed on that date. After the new ADLT initial period is over, payment would be based on the weighted median methodology. CMS also discusses how it proposes to implement its authority under PAMA to recoup Medicare payment amounts during the new ADLT initial period if they exceed 130% of the Medicare payment amount determined by the weighted median methodology.

Implementation Schedule

CMS proposes the following schedule for implementation of its new reporting and payment methodology for purposes of CY 2017 payment rates:

  • First data collection period: July 1, 2015 through December 31, 2015
  • First data reporting period (for applicable laboratories to report applicable information to CMS): January 1, 2016 through March 31, 2016
  • Annual laboratory public meeting for new tests (that are not new ADLTs) for which there is no private payor data collected: mid-July 2016
  • Preliminary gapfilled/crosswalked rates for CY 2017 published: early September 2016 (with approximately 30 days for public comments)
  • Final CY 2017 CLFS fee rates available on the CMS website: November 1, 2016
  • Statutory implementation date of new CLFS: January 1, 2017.

Other Policy Issues and Comment Opportunity

The proposed rule also addresses a variety of other related policy issues, including: the schedule for reporting applicable information to CMS; certification of submitted information; civil monetary penalties for applicable laboratories that fail to report or that make a misrepresentation or omission in reporting applicable information); confidentiality and public release of limited data; temporary coding for new tests; the local coverage determination process; and the potential designation of Medicare Administrative Contractors (MACs) for laboratory tests (CMS is not proposing provisions related to the MACs at this time).

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions